Virbac Announces The Arrival Of Canigen® Bb, A New Injectable Bordetella Bronchiseptica Vaccine For Dogs
4 weeks ago 
472 views
Virbac is pleased to announce the addition of Canigen® Bb, a new injectable Bordetella bronchiseptica vaccine for dogs, to their comprehensive companion animal vaccine range.
Canigen® Bb, an inactivated subunit vaccine, provides active immunisation against Bordetella bronchiseptica in dogs to reduce clinical signs of upper respiratory tract disease, whilst also reducing bacterial shedding post-infection.
Administered via subcutaneous injection, Canigen® Bb offers clinicians a new tool in the fight against kennel cough in dogs where intra-nasal Bordetella bronchiseptica vaccination is not possible or preferred.
Licensed for use in dogs from 6 weeks of age, Canigen® Bb extends protection against Bordetella bronchiseptica in dogs vaccinated with Canigen® KC in the last 12 months for a further year with a single dose.
Canine infectious respiratory disease (CIRD), otherwise known as kennel cough or infectious tracheobronchitis, is widely recognised as one of the most common infectious diseases in dogs1. Bordetella bronchiseptica is a clinically significant pathogen for the disease with 78.7% of dogs with acute respiratory signs testing positive for the bacteria2. 45.6% of clinically healthy dogs also tested positive for Bordetella bronchiseptica, illustrating that clinically healthy dogs can carry respiratory pathogens and could act as sources of infection for susceptible dogs2.
‘Canigen® Bb offers clinicians an ideal solution to provide protection against Bordetella bronchiseptica in dogs where, for whatever reason, administering an intra-nasal vaccine is difficult or in pets who are in contact with known immunocompromised individuals where a live aerosolised vaccine may be less appropriate’ said Andrew Connolly, Marketing Director – UK & Ireland at Virbac. ‘It is our hope that Canigen® Bb will increase the overall uptake of Bordetella bronchiseptica vaccination to provide increased protection against this widely prevalent and clinically significant disease’.
Canigen®Bb is conveniently presented as a ready to use formula in a 10ml multi-dose bottle and can be stored at room temperature (2°C - 25°C) for up to 4 weeks once broached. It can be administered concurrently (at the same time but separate injections) with Canigen® DHP, Canigen® DHPPi, Canigen® Pi & Canigen® Lepto 4.
To find out more about Canigen® Bb, or to learn how Virbac’s vaccine support could benefit you and your practice, please speak to your local Virbac Territory Manager.
- Buonavoglia C., Martella V. Canine respiratory viruses. Veterinary Research. 2007; 38:355–373.
- Schulz BS, Kurz S, Weber K, Balzer HJ, Hartmann K. Detection of respiratory viruses and Bordetella bronchiseptica in dogs with acute respiratory tract infections. Vet J. 2014 Sep; 201(3):365-9.
More from Virbac Animal Health
- Will Balhatchet crowned Young Dairy Vet of the Year 2024
- ‘Twist Your View on Otitis Treatment’: Virbac Invites Delegates to Complimentary CPD Webinar
- New Advanced Oral Care Now Available in the Virbac VETERINARY HPM® Small & Toy Range
- Virbac Launches Cortotic, a Revolutionary Treatment for Canine Otitis Externa – Without an Antimicrobial!
- Virbac provides vets with reproductive educational resource following WSAVA guidelines publication
